posted on 2022-02-15, 22:33authored byWilliam P. Miller, Allyson L. Toro, Siddharth Sunilkumar, Shaunaci A. Stevens, Ashley M. VanCleave, David L. Williamson, Alistair J. Barber, Michael D. Dennis
Clinical
studies support a role for the protein regulated in development and DNA damage
response 1 (REDD1) in ischemic retinal complications. To better understand how REDD1 contributes to retinal
pathology, we examined human single cell sequencing datasets and found
specificity of REDD1 expression that was consistent with markers of retinal
Müller glia. Thus, we investigated the hypothesis that REDD1 expression
specifically in Müller
glia contributes to diabetes-induced retinal pathology. The retina of Müller glia specific REDD1
knockout (REDD1 mgKO) mice exhibited dramatic attenuation of REDD1 transcript
and protein expression. In the retina of streptozotocin-induced diabetic
control mice, REDD1 protein expression was enhanced coincident with an increase
in oxidative stress.
In the retina of diabetic REDD1 mgKO mice there was no increase in REDD1
protein expression and oxidative stress was reduced as compared to diabetic control
mice. In both Müller glia within the retina of diabetic mice and human Müller cell cultures exposed to hyperglycemic conditions,
REDD1 was necessary for increased expression of the gliosis marker glial
fibrillary acidic protein.
The effect
of REDD1 deletion in preventing gliosis was associated with suppression of
oxidative stress and required the antioxidant transcription factor Nrf2. In contrast to diabetic controlmice, diabetic
REDD1 mgKO mice did not exhibit retinal thinning, increased markers of
neurodegeneration within the retinal ganglion cell layer, or deficits in visual
function. Overall, the findings support a key role for Müller glial REDD1 in the
failed adaptive response of the retina to diabetes that includes gliosis,
neurodegeneration, and impaired vision.
Funding
This research was supported by the American Diabetes Association Pathway to Stop Diabetes grant 1-14-INI-04, National Institutes of Health grants R01 EY029702, R01 EY032879 (to MDD), and F31 EY031199 (to WPM).